Logo image of DNTH

DIANTHUS THERAPEUTICS INC (DNTH) Stock Fundamental Analysis

USA - NASDAQ:DNTH - US2528281080 - Common Stock

36 USD
+0.35 (+0.98%)
Last: 10/20/2025, 8:00:01 PM
35.49 USD
-0.51 (-1.42%)
After Hours: 10/20/2025, 8:00:01 PM
Fundamental Rating

3

DNTH gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. While DNTH has a great health rating, there are worries on its profitability. DNTH is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DNTH has reported negative net income.
In the past year DNTH has reported a negative cash flow from operations.
In the past 5 years DNTH always reported negative net income.
DNTH had a negative operating cash flow in each of the past 5 years.
DNTH Yearly Net Income VS EBIT VS OCF VS FCFDNTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of DNTH (-35.19%) is better than 62.92% of its industry peers.
Looking at the Return On Equity, with a value of -37.86%, DNTH is in the better half of the industry, outperforming 73.22% of the companies in the same industry.
Industry RankSector Rank
ROA -35.19%
ROE -37.86%
ROIC N/A
ROA(3y)-33.05%
ROA(5y)-36.6%
ROE(3y)-40.68%
ROE(5y)-43.06%
ROIC(3y)N/A
ROIC(5y)N/A
DNTH Yearly ROA, ROE, ROICDNTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DNTH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DNTH Yearly Profit, Operating, Gross MarginsDNTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

8

2. Health

2.1 Basic Checks

DNTH does not have a ROIC to compare to the WACC, probably because it is not profitable.
DNTH has more shares outstanding than it did 1 year ago.
The number of shares outstanding for DNTH has been increased compared to 5 years ago.
There is no outstanding debt for DNTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DNTH Yearly Shares OutstandingDNTH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
DNTH Yearly Total Debt VS Total AssetsDNTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 35.60 indicates that DNTH is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 35.60, DNTH belongs to the best of the industry, outperforming 95.13% of the companies in the same industry.
DNTH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 35.6
ROIC/WACCN/A
WACC9.37%
DNTH Yearly LT Debt VS Equity VS FCFDNTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 13.12 indicates that DNTH has no problem at all paying its short term obligations.
The Current ratio of DNTH (13.12) is better than 87.27% of its industry peers.
A Quick Ratio of 13.12 indicates that DNTH has no problem at all paying its short term obligations.
DNTH has a Quick ratio of 13.12. This is amongst the best in the industry. DNTH outperforms 87.27% of its industry peers.
Industry RankSector Rank
Current Ratio 13.12
Quick Ratio 13.12
DNTH Yearly Current Assets VS Current LiabilitesDNTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

DNTH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.34%, which is quite impressive.
DNTH shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.99%.
EPS 1Y (TTM)41.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-72.55%
Revenue 1Y (TTM)17.99%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-89.64%

3.2 Future

DNTH is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -9.16% yearly.
DNTH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 102.29% yearly.
EPS Next Y-33.19%
EPS Next 2Y-17.92%
EPS Next 3Y-14.62%
EPS Next 5Y-9.16%
Revenue Next Year-57.46%
Revenue Next 2Y-38.3%
Revenue Next 3Y-20.49%
Revenue Next 5Y102.29%

3.3 Evolution

DNTH Yearly Revenue VS EstimatesDNTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
DNTH Yearly EPS VS EstimatesDNTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DNTH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DNTH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DNTH Price Earnings VS Forward Price EarningsDNTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNTH Per share dataDNTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

A cheap valuation may be justified as DNTH's earnings are expected to decrease with -14.62% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.92%
EPS Next 3Y-14.62%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DNTH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DIANTHUS THERAPEUTICS INC

NASDAQ:DNTH (10/20/2025, 8:00:01 PM)

After market: 35.49 -0.51 (-1.42%)

36

+0.35 (+0.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-06 2025-11-06
Inst Owners101.08%
Inst Owner Change0.02%
Ins Owners0.01%
Ins Owner Change0%
Market Cap1.43B
Analysts88.42
Price Target62.42 (73.39%)
Short Float %17.27%
Short Ratio7.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.17%
Min EPS beat(2)1.02%
Max EPS beat(2)5.31%
EPS beat(4)3
Avg EPS beat(4)-2.26%
Min EPS beat(4)-22.05%
Max EPS beat(4)6.67%
EPS beat(8)5
Avg EPS beat(8)-69.03%
EPS beat(12)7
Avg EPS beat(12)-42.04%
EPS beat(16)9
Avg EPS beat(16)-31.44%
Revenue beat(2)1
Avg Revenue beat(2)-18.17%
Min Revenue beat(2)-78.11%
Max Revenue beat(2)41.76%
Revenue beat(4)3
Avg Revenue beat(4)51.48%
Min Revenue beat(4)-78.11%
Max Revenue beat(4)228.36%
Revenue beat(8)7
Avg Revenue beat(8)133.15%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)25.54%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.02%
EPS NY rev (1m)1.04%
EPS NY rev (3m)-1.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-36.8%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-37.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 295.18
P/FCF N/A
P/OCF N/A
P/B 4.73
P/tB 4.73
EV/EBITDA N/A
EPS(TTM)-3.25
EYN/A
EPS(NY)-3.62
Fwd EYN/A
FCF(TTM)-2.52
FCFYN/A
OCF(TTM)-2.52
OCFYN/A
SpS0.12
BVpS7.62
TBVpS7.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.19%
ROE -37.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.05%
ROA(5y)-36.6%
ROE(3y)-40.68%
ROE(5y)-43.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.04%
Cap/Sales 2.6%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.12
Quick Ratio 13.12
Altman-Z 35.6
F-Score3
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)24.18%
Cap/Depr(5y)31.02%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-72.55%
EPS Next Y-33.19%
EPS Next 2Y-17.92%
EPS Next 3Y-14.62%
EPS Next 5Y-9.16%
Revenue 1Y (TTM)17.99%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-89.64%
Revenue Next Year-57.46%
Revenue Next 2Y-38.3%
Revenue Next 3Y-20.49%
Revenue Next 5Y102.29%
EBIT growth 1Y-88.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-37.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.99%
OCF growth 3YN/A
OCF growth 5YN/A